<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Sabra Health Care REIT, Inc.

    Sabra Health Care REIT, Inc.

    As of June 30, 2019, Sabra’s investment portfolio included 432 real estate prope...

    As of June 30, 2019, Sabra’s investment portf...

    Filing Type:    PU
    Maternova, Inc.

    Maternova, Inc.

    Maternova, Inc. is the trusted resource for cutting edge medical innovations in ne...

    Maternova, Inc. is the trusted resource for cut...

    Amount Raised:    $104,976.00
    Fundraising Status:    EC
    Filing Type:    CF
    Surface Oncology, Inc.

    Surface Oncology, Inc.

    Surface Oncology is an immuno-oncology company on a mission to break through and d...

    Surface Oncology is an immuno-oncology company ...

    Filing Type:    PU
    Hepion Pharmaceuticals, Inc.

    Hepion Pharmaceuticals, Inc.

    Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical stage biopharmaceutical compan...

    Hepion Pharmaceuticals (Nasdaq: HEPA) is a clin...

    Filing Type:    PU
    CytoDyn Inc.

    CytoDyn Inc.

    CytoDyn is a publicly traded late stage biotechnology company developing innovativ...

    CytoDyn is a publicly traded late stage biotech...

    Filing Type:    PU
    Forty Seven, Inc.

    Forty Seven, Inc.

    Forty Seven is a clinical-stage immuno-oncology company focused on developing nove...

    Forty Seven is a clinical-stage immuno-oncology...

    Filing Type:    PU
    GlycoMimetics, Inc.

    GlycoMimetics, Inc.

    At GlycoMimetics, we are committed to helping to make a difference in the lives of...

    At GlycoMimetics, we are committed to helping t...

    Filing Type:    PU
    Allogene Therapeutics, Inc.

    Allogene Therapeutics, Inc.

    Allogene Therapeutics is a clinical stage biotechnology company pioneering the dev...

    Allogene Therapeutics is a clinical stage biote...

    Filing Type:    PU
    Sunesis Pharmaceuticals, Inc.

    Sunesis Pharmaceuticals, Inc.

    Sunesis is a biopharmaceutical company focused on the development and commercializ...

    Sunesis is a biopharmaceutical company focused ...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.